New combo shows promise for tough bile duct cancer in early trial
NCT ID NCT07530445
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (iparomlimab, tuvonralimab, chemotherapy, and lenvatinib) as a second-line treatment for people with advanced bile duct cancer that has worsened after first-line therapy. The goal is to see if this approach can help control the cancer and improve survival. About 40 participants will be enrolled at a single center in China.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECOND-LINE THERAPY FOR UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhiqiang Wang, guangzhou, Other (Non U.S.) 510000 Recruiting
RECRUITINGGuangzhou, China